Long-Term Responders to Erlotinib for Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor: Two Case Reports and a Single-Institutional Retrospective Study

Erlotinib is an oral and reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and is now used exclusively to non-small cell lung carcinoma (NSCLC) harboring mutated EGFR. However, there was historically a transient period when erlotinib was widely used regardless of EGFR muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Minami, Seigo, Shoshihara, Nao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990727/
https://www.ncbi.nlm.nih.gov/pubmed/36895989
http://dx.doi.org/10.14740/wjon1554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990727/
https://www.ncbi.nlm.nih.gov/pubmed/36895989
http://dx.doi.org/10.14740/wjon1554

Ejemplares similares